News
June brought major prostate cancer updates, and CURE is sharing the latest FDA approvals, label expansions, and emerging data ...
Pfizer's broader portfolio and higher dividend yield give it an edge over Bristol Myers in the oncology showdown.
14d
MedPage Today on MSNBlood Tests for Early Cancer; Rethinking Asbestos Ban; Reducing Depression in CancerGrail announced that results from the registrational PATHFINDER 2 study of its Galleri multi-cancer early detection test ...
FDA approves updated labeling for Talzenna plus Xtandi in men with HRR gene-mutated metastatic prostate cancer, showing a 14-month survival benefit.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results